Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Trellus Health PLC ( (GB:TRLS) ) just unveiled an update.
Trellus Health PLC announced its unaudited interim results for the first half of 2025, highlighting a reduction in its adjusted EBITDA loss to $2.6 million and a significant increase in revenue to $379,000. The company has made strategic agreements, including a collaboration with Johnson & Johnson and a renewed licensing agreement with Pfizer, to strengthen its market positioning. Despite a decrease in net cash, Trellus Health plans to explore fundraising options to extend its cash runway and support its commercial strategy. The company continues to focus on expanding its clinical trial vertical and enhancing its partnerships to drive growth.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company that provides value-based innovative solutions and services aimed at helping individuals with chronic conditions manage their health. The company offers Trellus Elevate®, a digital platform integrating data analytics with personalized resilience programs to manage complex chronic conditions, focusing initially on gastrointestinal conditions like Inflammatory Bowel Disease (IBD). Trellus Health works across pharmaceutical patient support programs, clinical trial services, and the U.S. health plan sector.
Average Trading Volume: 984,391
Technical Sentiment Signal: Sell
Current Market Cap: £1.29M
See more insights into TRLS stock on TipRanks’ Stock Analysis page.